<DOC>
	<DOCNO>NCT00169156</DOCNO>
	<brief_summary>To evaluate efficacy safety front-line treatment combine CHOP regimen rituximab patient age 60 80 year previously untreated AIL .</brief_summary>
	<brief_title>A Phase II Study Rituximab Combined With CHOP T-cell Angio-immunoblastic Lymphoma</brief_title>
	<detailed_description>This multicentric , open-label , non-randomized clinical study , evaluate efficacy safety front-line treatment combine CHOP regimen rituximab patient age 60 80 year previously untreated AIL . It anticipate 25 subject enrol 2 year ( 2005 / 2007 ) .Analysis perform every 5 patient ( base triangular test ) . The duration treatment period approximately 25 week patient follow Death . The total Duration study expect 2.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patients histologically proven Tcell angioimmunoblastic lymphoma ( AIL ) lymph node biopsy . Aged 60 80 year . Patient previously treat ( except corticosteroid provide initiate less 10 day inclusion ) . ECOG performance status 0 2 . With minimum life expectancy &gt; 3 month . Negative HIV , HBV HCV serological test &lt; 4 week ( except vaccination ) . Having previously sign write informed consent . Any histological type Tcell lymphoma . Central nervous system meningeal involvement lymphoma . Contraindication drug include RCHOP regimen . Concurrent severe disease ( accord investigator 's decision ) . Active bacterial , viral fungal infection . Poor renal function ( serum creatinine level &gt; 150 µmol/L ) impair liver function test ( total bilirubin level &gt; 30 µmol/L , transaminases &gt; 2.5 upper normal limit ) unless relate lymphoma . Poor bone marrow reserve define neutrophil &lt; 1.5 x 109/L platelet &lt; 100 x 109/L , unless relate bone marrow infiltration . Any history cancer last 5 year , exception non basal cell carcinoma skin situ carcinoma cervix . Treatment investigational drug within 30 day plan first cycle chemotherapy study . Patient tutelage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>T-cell angioimmunoblastic lymphoma</keyword>
	<keyword>Rituximab</keyword>
</DOC>